The well-publicized growth of the diabetic population worldwide has created a market opportunity for therapies that address three microvascular complications of diabetes: nephropathy, neuropathy, and retinopathy. Chronic hyperglycemia puts all diabetics at risk of developing these conditions, which can exact a considerable toll on the diabetic patient. Microvascular Complications of Diabetes, a new Decision Resources study, evaluates these chronic complications and the drug development efforts underway to fulfill the significant unmet needs associated with each disease.
During the 2000-2010 forecast period of this study, the factors driving drug development in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will be as diverse as the diseases themselves:
Neuropathic pain is notoriously difficult to treat.
Because disease etiology and pathophysiology are poorly understood, as many as 50% of diabetic neuropathy patients cannot achieve adequate symptom relief, despite the variety of agents available. The unmet need for effective therapies is considerable, particularly for a novel therapy that effectively targets disease pathology. Aldose reductase inhibitors (ARIs), growth factors, NMDA antagonists, and other emerging therapies are all expected to establish a foothold in the neuropathy market, but a need will still exist for safe, effective, disease-modifying agents.
No proven drug therapy exists for diabetic retinopathy.
Surgical treatments such as photocoagulation and vitrectomy are the gold standards, but physicians are eager for an effective pharmaceutical option. The most promising agents in development are the protein kinase-C inhibitors (e.g., Eli Lilly's LY-333531), which are poised to enter the U.S. and European markets by 2004 and 2003, respectively, and the Japanese market by 2008. Given that the near lack of pharmacotherapy has kept drug-treated rates below 15%, this class represents enormous market potential.
The diabetic nephropathy sector poses significant challenges.
This market is characterized by a low level of unmet need for new pharmacological approaches. Antihypertensives, when utilized aggressively and in conjunction with superb glycemic control, are highly effective for the prevention and treatment of nephropathy.
Microvascular Complications of Diabetes offers invaluable market intelligence for pharmaceutical companies competing in this market. This study is part of Mosaic, one of six Pharmacor services from Decision Resources that evaluate the commercial potential of drugs in research and development.
Macrovascular complications are discussed in the recent Decision Resources study Cardiovascular Complications of Diabetes.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or email@example.com.
In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or firstname.lastname@example.org. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,